Stockscreener 앱 받기
14.52
0.17%
0.005
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Federal Circuit Rules Written Description Standard Governs Patent Priority In Enanta Pharmaceuticals v. Pfizer (PFE) - londoninsider.co.uk
Price to sales forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2500 Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2000 Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry - Moomoo
Enanta Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
AbbVie, Enanta announce EU label expansion for hepatitis C therapy, Maviret - MSN
Enanta Pharmaceuticals (ENTA) moves 5.2% higher: Will this strength last? - MSN
Enanta Pharmaceuticals sets out pipeline catalysts, shares watched by biotech investors - AD HOC NEWS
Enanta Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ENTA) - TradingView
Pfizer patent win against Enanta over COVID pill upheld by appeals court - MSN
Price to book forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Price to earnings forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enterprise value to revenue forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView
Price to book forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView
ENTA Forecast — Price Target — Prediction for 2027 - TradingView
PATENT—Fed. Cir.: Pfizer Inc. prevails in coronavirus-treatment patent dispute with biotechnology company - VitalLaw.com
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance
EC approves label expansion for Enanta’s Maviret in acute HCV infection - The Pharma Letter
Form 8K Enanta Pharmaceuticals Inc For: 23 June - Investing.com UK
Federal appeals court upholds invalidity of Enanta patent in Pfizer case By Investing.com - Investing.com South Africa
Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com South Africa
Federal appeals court upholds invalidity of Enanta patent in Pfizer case - Investing.com UK
H.C. Wainwright reiterates Enanta stock rating on FDA alignment - Investing.com UK
Enanta Faces Patent Setback in Paxlovid Litigation - TipRanks
H.C. Wainwright reiterates Enanta stock rating on FDA alignment By Investing.com - Investing.com South Africa
[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event - Stock Titan
CAFC Affirms Enanta Coronavirus Patent Invalid for Lack of Written Description Support in Provisional Application - IPWatchdog.com
Pfizer Keeps Win in Patent Lawsuit Aimed at Paxlovid Antiviral - Bloomberg Law News
Enanta (ENTA) Secures EU Approval for Maviret Treatment - GuruFocus
ENTA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
Enanta Pharmaceuticals? Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - marketscreener.com
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - BioSpace
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET - Business Wire
Enanta Pharmaceuticals (ENTA) reports Q2 loss, lags revenue estimates - MSN
Enanta Pharmaceuticals Inc (ENTA) Institutional Confidence - TradingKey
Why (ENTA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Enanta Pharmaceuticals Inc (ENTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
1.16%
0.48%
자본화:
|
볼륨(24시간):